Foundation year: 2005

NACE classifier: Farmaceitisko pamatvielu ražošana; Tehniskā pārbaude un analīze

Valid certificates:

GMP

Turnover in the last 5 years

Millions EUR

Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.

PHARMIDEA is a pharmaceutical manufacturer of generic drugs. The core competence is manufacturing small batch size sterile products in vials - lyophilized and liquid forms.

Company services include: contract manufacturing, technology development, validation, elaboration of specifications and test methods, stability studies, documentation development for product registration, Out-licensing and serialization.

Export volume over the last 5 years

Millions EUR

Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.

Main markets

  1. 1. Czech Republic
  2. 2. France
  3. 3. Germany
  4. 4. Israel
  5. 5. Russia
  6. 6. Sweden
  7. 7. Turkey
  8. 8. Ukraine
  9. 9. Vietnam

Target Markets

  1. 1. Australia
  2. 2. Belarus
  3. 3. China
  4. 4. Egypt
  5. 5. Jordan
  6. 6. Kazakhstan
  7. 7. Kuwait
  8. 8. Lebanon
  9. 9. Malaysia
  10. 10. Morocco
  11. 11. Saudi Arabia
  12. 12. Tunisia
  13. 13. Ukraine
  14. 14. United Arab Emirates

In which areas are looking for cooperation

  • Manufacturing of active pharmaceutical ingredients and pharmaceuticals

Investing in R&D

Millions EUR

Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.

Products

Atosiban

Atosiban 6.75mg/0.9ml solution for injection Atosiban 37.5mg/5ml concentrate for solution for infusion Atosiban is an inhibitor of the hormones oxytocin and vasopressin and indicated to delay imminent preterm birth for women with a gestational age from 24 until 33 completed weeks.

Carbetocin

Carbetocin 100 micrograms/ml solution for injection Carbetocin is a long-acting synthetic Oxytocin analogue indicated for the prevention of uterine atony following delivery of the infant by caesarean section.
Dexmedetomidine 100 µg/ml concentrate for solution for infusion Dexmedetomidine is a highly selective α2-adrenergic agonist indicated for light to moderate sedation in an intensive care setting without the risk of respiratory depression.

Foundation year: 2005

NACE classifier: Farmaceitisko pamatvielu ražošana; Tehniskā pārbaude un analīze

Turnover in the last 5 years

Millions EUR

Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.

2018 2019 2020 2021 2022
5298638 7959371 8385706 7443716 7447302

In which areas are looking for cooperation

  • Manufacturing of active pharmaceutical ingredients and pharmaceuticals

Export volume over the last 5 years

Millions EUR

Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2018 to 2022.

2018 2019 2020 2021 2022
5033706.1 7768315 7798706 6997093 7372000

Main markets

  1. 1. Czech Republic
  2. 2. France
  3. 3. Germany
  4. 4. Israel
  5. 5. Russia

Target Markets

  1. 1. Australia
  2. 2. Belarus
  3. 3. China
  4. 4. Egypt
  5. 5. Jordan
  6. 6. Kazakhstan
  7. 7. Kuwait
  8. 8. Lebanon
  9. 9. Malaysia
  10. 10. Morocco
  11. 11. Saudi Arabia
  12. 12. Tunisia
  13. 13. Ukraine
  14. 14. United Arab Emirates

Investing in R&D

Millions EUR

Source: Data collected by the Association of Latvian Chemical and Pharmaceutical Entrepreneurs from 2019 to 2023.

2018 2019 2020 2021 2022
929577 1113157 1250000 1270000 1478000

PHARMIDEA SIA 

Description about enterprise:

PHARMIDEA is a pharmaceutical manufacturer of generic drugs. The core competence is manufacturing small batch size sterile products in vials - lyophilized and liquid forms.

Company services include: contract manufacturing, technology development, validation, elaboration of specifications and test methods, stability studies, documentation development for product registration, Out-licensing and serialization.

Valid certificates:

GMP

Products

Atosiban

Atosiban 6.75mg/0.9ml solution for injection Atosiban 37.5mg/5ml concentrate for solution for infusion Atosiban is an inhibitor of the hormones oxytocin and vasopressin and indicated to delay imminent preterm birth for women with a gestational age from 24 until 33 completed weeks.

Carbetocin

Carbetocin 100 micrograms/ml solution for injection Carbetocin is a long-acting synthetic Oxytocin analogue indicated for the prevention of uterine atony following delivery of the infant by caesarean section.
Dexmedetomidine 100 µg/ml concentrate for solution for infusion Dexmedetomidine is a highly selective α2-adrenergic agonist indicated for light to moderate sedation in an intensive care setting without the risk of respiratory depression.